Polsky Bruce's Form 4 filing
Atea Pharmaceuticals, Inc.AVIR · filed Nov 18, 2026
- Accession no.
- 0001193125-26-467490
- Filed
- Nov 18, 2026, 8:59 PM ET
- Trade date
- Nov 16-18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $168.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Polsky BruceCIK 0001508458 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Common Stock | MOption exerciseAcquired | +48,028 | $1.24 | +$59,554.72 | 172,834 | Direct | |
| Nov 16, 2026 | Common Stock | SSaleDisposed | −14,254 | $4.27F1 | −$60,840.35 | 158,580 | Direct | |
| Nov 17, 2026 | Common Stock | MOption exerciseAcquired | +8,720 | $1.24 | +$10,812.8 | 167,300 | Direct | |
| Nov 17, 2026 | Common Stock | SSaleDisposed | −8,720 | $4.03F2 | −$35,155.55 | 158,580 | Direct | |
| Nov 18, 2026 | Common Stock | MOption exerciseAcquired | +18,252 | $1.24 | +$22,632.48 | 176,832 | Direct | |
| Nov 18, 2026 | Common Stock | SSaleDisposed | −18,252 | $3.95F3 | −$72,099.05 | 158,580 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Common Stock | MOption exerciseDisposed | −48,028 | $0.00 | $0 | 26,972 | Direct | |
| Nov 17, 2026 | Common Stock | MOption exerciseDisposed | −8,720 | $0.00 | $0 | 18,252 | Direct | |
| Nov 18, 2026 | Common Stock | MOption exerciseDisposed | −18,252 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.20 to $4.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $4.00. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.